Best Life Sciences Platforms and Tools Companies in Israel
The 109 best Life Sciences Platforms and Tools companies in Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Scopio Labs.
Israel's Life Sciences Platforms and Tools sector is one of the more quietly ambitious corners of the country's tech economy, and this directory ranks the 109 companies we track by disclosed equity funding and recent funding momentum. Total disclosed funding sits at $377M across that cohort, with no unicorns yet, but the spread is telling. Scopio Labs leads at $115M, NovellusDx has pulled $86M, and Oncohost sits at $43M. That's three companies accounting for a significant chunk of the pool while the rest of the field is still early.
So what's the macro case? The global life sciences platforms and tools market was valued at roughly $89.4B in 2020 and is forecast to reach $183.8B by 2027, a CAGR of around 10.8%. Demand is moving on quantitative accuracy improvements and advances in information sciences, though regulatory challenges remain a real friction point for any company trying to scale clinical applications. Investors like aMoon and Pontifax are active here, which tells you something about where conviction is sitting. If you're sizing up this field, the funding gap between the top three and the rest of the 109 is the number worth watching.
- ResearchAndMarkets.com
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in Israel
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Scopio Labs Developer of digital imaging platforms for hematology 83AI top 15%Funding top 19%Product top 21%Moat top 28% All 11 signals ▾AItop 15% Fundingtop 19% Producttop 21% Moattop 28% Techtop 29% Patentstop 31% Innovationtop 34% Growthtop 35% Markettop 45% Globalbottom 43% Newsbottom 17% AI: Holds AI/ML patents (G06N-family CPC) Funding: Raised $115M across 7 rounds · 7 rounds over 9 yrs (0.8/yr) rank vs industry peers · Fliar Intelligence Index 83/100 | $115M | 10 mo ago | 124 | — | WordPressApple iCloud MailGoogle Workspace+38 | Top 5M | 72 patents Automated digital microscopy imaging and slide handling for high‑throughput pathology | 1 launch · 1 award |
| 2 | NovellusDx Developer of technology for precision cancer diagnosis and therapies | $86M | 69 mo ago | 49 | — | — | — | 46 patents Patient-specific cancer mutation identification, functional validation, and drug response profiling | — |
| 3 | ONCOHOST AI-based oncology therapy plan solution for professionals 64Patents top 27%Moat top 28%Talent top 28%Innovation top 29% All 10 signals ▾Patentstop 27% Moattop 28% Talenttop 28% Innovationtop 29% AItop 30% Fundingtop 31% Techbottom 42% Marketbottom 41% Globalbottom 35% Newsbottom 18% Patents: 55 patents matched (strict assignee match) · 38 filings since 2022 vs 17 in 2017-21 Moat: Editorial + unicorn rating 8/10 · IP moat: 55 patents rank vs industry peers · Fliar Intelligence Index 64/100 | $43M | 13 mo ago | 48 | Yuval Shaked Co-Founder | Cart FunctionalityWebflowSalesforce+11 | Top 50M | 55 patents AI-driven predictive analytics for personalized cancer treatment response and biomarker identification | 2 job openings |
| 4 | Mapi Pharma Clinical stage pharmaceutical company developing extended release versions of generic drugs. | $40M | 72 mo ago | 38 | Ehud Marom Chairman & Ceo | WordPressMySQLPHP+15 | Top 10M | 325 patents Patents concentrated in health & consumer products | — |
| 5 | Biomica Developer of microbiome-based therapeutics to treat immune-mediated and infectious diseases | $20M | 37 mo ago | 15 | Elran Haber CEO | WordPressMySQLPHP+16 | Top 50M | 38 patents Therapeutic and diagnostic microbial consortia for human health applications | — |
| 6 | Core Dynamics Organ preservation technologies for the freezing, thawing, and freeze-drying of cells. | $18M | 206 mo ago | — | Sachi Norman CEO | — | — | 11 patents Cryogenic preservation and controlled cooling of biological tissues and organs | — |
| 7 | Curesponse Provider of a tissue culture system to analyze cancer growth and drug response | $14M | 55 mo ago | 16 | Guy Neev Co-Founder & CEO | WordPressMySQLPHP+17 | Top 50M | — | — |
| 8 | Vortex Imaging Medical tech company offering ultrasound imaging devices using UV radiations 24Funding top 35%Moat top 38%Patents top 45%Talent bottom 49% All 8 signals ▾Fundingtop 35% Moattop 38% Patentstop 45% Talentbottom 49% Innovationbottom 48% Techbottom 46% Globalbottom 40% Marketbottom 22% Funding: Raised $12.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 9 patents rank vs industry peers · Fliar Intelligence Index 24/100 | $12M | 1 mo ago | 9 | Uri Tal Co-Founder | WixSentryBootstrap+11 | Top 50M | 9 patents Advanced full-waveform inversion for high-resolution reflection ultrasound tomography | — |
| 9 | IntecPharma Drug delivery technology to improve pharmacokinetics and pharmacodynamics of drugs for Parkinson's, insomnia… | $5M | 78 mo ago | 14 | — | — | — | — | — |
| 10 | SpacePharma Provider of microgravity research solutions for researchers, institutes, and commercial companies | $5M | 106 mo ago | 13 | Martin Aebi Co-Founder | WebflowjsDelivrGoogle Hosted Libraries+9 | Top 50M | 4 patents Microfluidic on‑orbit drug synthesis and precise liquid/powder delivery systems | 1 launch |
| 11 | BioCep Immunomagnetic cell isolation platform | $5M | 148 mo ago | 5 | Hannoch Marksheid Co-Founder & CEO | — | — | 20 patents Magnetic isolation of rare cells for biomedical research and diagnostics | — |
| 12 | Accellta Solutions for the mass production of human embryonic and induced pluripotent stem cells | $4M | 133 mo ago | 14 | — | — | — | 43 patents Provides specialized suspension culture media for pluripotent stem cell production. | — |
| 13 | SmartZyme Provider of proprietary protein design and engineering technology to develop products for diabetes market | $4M | 99 mo ago | 14 | — | — | — | — | — |
| 14 | TACount Imaging-based microbiological testing technology | $2M | 181 mo ago | — | Isak Duenyas Founder | — | — | — | — |
| 15 | TargetGene Biotechnologies Platform for in-vivo assembling of nucleases in plant cells | $930K | 38 mo ago | 6 | Dan Weinthal Co-Founder And Coo | — | — | 46 patents CRISPR-based gene editing platforms for immune cell engineering and targeted DNA modification | — |
| 16 | Rosetta Green Provider of tech news, computer repair tips, and gadget information | $814K | 178 mo ago | — | Aviad Friedman Chairman & CEO | — | — | 12 patents Genetically engineered crops improving oil yield, stress tolerance, and nitrogen efficiency | — |
| 17 | IDEA Biomedical Biological cell imaging system for drug discovery | $669K | 93 mo ago | — | Shlomo Turgeman Founder & CEO | WordPressMySQLPHP+40 | Top 50M | 13 patents Automated optical focusing and high-throughput plate imaging for biomedical assays. | — |
| 18 | LipoMedix Provider of Israeli clinical-stage biotech developing PEG-ylated liposomal Mitomycin drugs for cancer | $639K | 78 mo ago | — | Alberto Gabizon Founder & CEO | — | — | — | — |
| 19 | Minovia Therapeutics Provider of cell therapy treatment for mitochondrial disease | $616K | 9 mo ago | 32 | Natalie Yivgi-Ohana CEO | WordPressMySQLPHP+18 | Top 10M | 146 patents Therapeutic delivery of functional mitochondria via stem cells for disease treatment | — |
| 20 | Polyol Biotech Developer of PFA-based cream for reducing ultraviolet radiation damage to the skin | $445K | 213 mo ago | — | Shai Meretzki Founder & Partner | — | — | 9 patents Natural polyhydroxylated fatty alcohols from avocado seed for cosmetic and pharmaceutical use | — |
| 21 | NextFerm Provider of non-GMO technology for improved yeast strains | $111K | 77 mo ago | 30 | Boaz Noy Chief Executive Officer | — | — | — | — |
Top 12 Life Sciences Platforms and Tools companies in Israel
#1
Series B · Ramat Gan, Tel Aviv District · founded 2020 · 9 employees$12Mraised▾
Medical tech company offering ultrasound imaging devices using UV radiations. It uses hypercompute imaging technology for ultrasound imaging modality, based on geophysics algorithms and computational software interface with GPUs on the cloud.
- May 2026Series B$12M
#2
Series D · Tel Aviv, Tel Aviv · founded 2014 · 124 employees$115Mraised▾
Developer of digital imaging platforms for hematology. The company uses computational photography to capture high-resolution (100X) full-field images of peripheral blood smears (PBS) and bone marrow aspirates (BMA), allowing labs to analyze entire slides without losing resolution or field of view.
- Jul 2025Series D$10M
- Jul 2024Series D$42M
- Sep 2022Conventional Debt$15M
- Feb 2022Series C$50M
#3
Series C · Binyamina Giv at Ada, Haifa District · founded 2017 · 48 employees$43Mraised▾
AI-based oncology therapy plan solution for patients and professionals. The company has developed a proprietary proteomic analysis that can analyze the proteomic changes in the blood sample induced by the patient in response to cancer therapy. The company also provide treatment strategy to improve the effectiveness of therapy. It also provides consultancy services to patients, oncologists, nurses, and pharma companies among others. The company has developed PROphet which is a bioinformatics tool used to identify proteomic patterns related to therapy.
- May 2025Grant (prize money)$2.8M
- May 2022Series C$35M
- Jan 2021Series B$8M
- Jan 2020Grant (prize money)—
#4
Funding Raised · Tirat Carmel, Haifa District · founded 2011 · 32 employees$616.1Kraised▾
Minovia provides cell therapy treatment for mitochondrial disease. The company uses Mitochondria Augmentation Therapy (MAT) a proprietary method of isolating mitochondria from white blood cells or placentas. The placental blood of women is used to extract mitochondria, then the cell collection is done, and after that apheresis where doctors can select hematopoietic stem cells from the white blood cells collected and then, over 24 hours, introduce the healthy mitochondria to the stem cells.
- Aug 2025Grant (prize money)$350K
- Oct 2022Grant (prize money)$266.1K
#5
Series C · Jerusalem, Jerusalem District · founded 2011 · 49 employees$85.5Mraised▾
Developer of technology for precision cancer diagnosis and therapies. The company's technology allows monitoring the outcomes of known and unknown DNA mutations, the function & clinical significance of each mutation, and the activity of the drug(s) on a specific tumor.
- Sep 2020Series C$57M
- Apr 2018Series B$6M
- Jun 2016Series B$12.5M
- Dec 2015Series A$10M
#6
Series B · Rehovot, Central District · founded 2017 · 15 employees$20Mraised▾
Developer of microbiome-based therapeutics to treat immune-mediated and infectious diseases. The company uses PRISM a proprietary computational analysis and predictive capabilities to identify BMC128 a combinational therapy for Non-small-cell lung carcinoma. Also, it develops drug candidates for multi drug-resistant organisms and gastrointestinal diseases.
- Apr 2023Series B$20M
#7
Series B · Ness Ziona, Center District · founded 2008 · 38 employees$40Mraised▾
Mapi Pharma develops extended release versions of generic drugs. It uses depot delivery systems that contain multiple doses of the drug that are released over a specified period of time at desired intervals. Its lead product is a once-a-month version of glatiramer acetate for the treatment of multiple sclerosis, which is about to enter pivotal phase III trials for the 505(b)(2) regulatory pathway. In addition, the company is also developing reformulated versions of pregabalin for neuropathic pain and epilepsy, and risperidone for the treatment of schizophrenia and bipolar disorder.
- Jun 2020Series B$20M
- Nov 2018Series B$10M
- Aug 2017Series B$10M
- 2016Series A$10M
#8
Series B · Rehovot, Central District · founded 2018 · 16 employees$14Mraised▾
Provider of a tissue culture system to analyze cancer growth and drug response. It preserves the cancer tissue (vasculature and immune system) to detect cancer growth in the body. It offers cResponse test that assesses individual patient’s tumor tissue via a biopsy or surgery, responds to a variety of cancer treatments. The test is combined with genomic analysis, for optimal adjustment of each cancer patient’s treatment.
#9
Deadpooled · Ness Ziona, Center District · founded 2005$17.9Mraised▾
Core Dynamics researches and develops technology for the freezing, thawing, and freeze-drying of cells and cell tissue for organ preservation. The company's cryopreservation technologies & protocols can be used in the field of orthopedic procedures.
- Apr 2009Series B$17.9M
#10
Deadpooled · Jerusalem, Jerusalem District · founded 2003 · 14 employees$5Mraised▾
Intec Pharma is a clinical stage biopharmaceutical company developing drugs based on its proprietary Accordion Pill platform technology. Accordion Pill is an oral drug delivery system to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. It currently has three drugs in clinical trials: Accordion pill carbidopa, or AP-CDLD, for the indication of treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients (Phase 2/3), and Accordion Pill - Zaleplon or AP-ZP, for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance (Phase 2) and an undisclosed drug, for prevention and treatment of small bowel NSAID-induced ulcers (Phase 1).
- Dec 2019Post IPO$10M
- Aug 2013PE$5M
#11
Funding Raised · Rehovot, Central District · founded 2012 · 6 employees$930Kraised▾
Platform for in-vivo assembling of nucleases in plant cells. It developes gene editing engine platform which enables in-vivo assembling of nucleases targeted to the cells genetic material using nucleic acid hybridization. The company core R and D involves gene targeting, genome engineering, and RNA‑guided genome editing technologies to alter genetic material for therapeutic purposes.
- Apr 2023Grant (prize money)$930K
#12
Series A · Herzliya, Tel Aviv · founded 2012 · 13 employees$5Mraised▾
Provider of microgravity research solutions for researchers, institutes, and commercial companies. The company has developed end-to-end miniaturized lab systems provided with sensors and readers, capable of working on different microgravity platforms, and assists its customers in all phases of performing experiments in microgravity, including experiment planning, preparation, execution in microgravity and result analysis.
- Jul 2017Grant (prize money)$1.1M
- Feb 2016Grant (prize money)$987.3K
- Oct 2015Series A$5M
- Jan 2015Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.